Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

Authors

Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
Qiang Gao (ORCID: https://orcid.org/0000-0002-6695-9906)
Shuang-Jian Qiu (ORCID: https://orcid.org/0000-0002-2659-472X)
Ying‐Hao Shen (ORCID: https://orcid.org/0000-0001-6476-0648)
Ying‐Hong Shi (ORCID: https://orcid.org/0000-0002-1833-8988)
Ziyi Wang (ORCID: https://orcid.org/0000-0002-4681-6588)
Jia Fan (ORCID: https://orcid.org/0000-0001-5158-629X)
Jian Zhou (ORCID: https://orcid.org/0000-0002-2118-1117)
Xiao‐Dong Zhu (ORCID: https://orcid.org/0000-0001-9864-6763)
Yuan Ji (ORCID: https://orcid.org/0000-0002-2631-9082)
Cheng Huang (ORCID: https://orcid.org/0000-0003-1358-6293)
Xiaoying Wang (ORCID: https://orcid.org/0000-0002-3855-4944)

Institutions

Sun Yat-sen University (CN)
Fudan University (CN)
Zhongshan Hospital (CN)
The First Affiliated Hospital, Sun Yat-sen University (CN)
Ministry of Education (ET)

Publication Details

Journal: BMJ Oncology
Published: 2024-12-01
DOI: https://doi.org/10.1136/bmjonc-2024-000578
Citations: 2
Primary Topic: Hepatocellular Carcinoma Treatment and Prognosis
Type: article
Field-Weighted Citation Impact: 0.74

Funders

Innovent Biologics
National Natural Science Foundation of China

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

Hui‐Chuan Sun, Qiang Gao, Shuang-Jian Qiu, Ying‐Hao Shen et al.

Dec 1, 2024

2 citations

BMJ Oncology

Hepatocellular Carcinoma Treatment and Prognosis

0.74

article

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

Hui‐Chuan Sun, Qiang Gao, Shuang-Jian Qiu, Ying‐Hao Shen, Ying‐Hong Shi, Ziyi Wang, Jia Fan, Jian Zhou, Xiao‐Dong Zhu, Yuan Ji, Cheng Huang, Xiaoying Wang

December 1, 2024article en

2 citations

Abstract

No abstract available for this paper.

BMJ OncologyVol. 3(1)

Sun Yat-sen University (CN), Fudan University (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Ministry of Education (ET)

Innovent Biologics, National Natural Science Foundation of China

Good health and well-being

Openalex Percentile: Top 26%

Hepatocellular Carcinoma Treatment and Prognosis

0.74

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis — Hui‐Chuan Sun, Qiang Gao, et al. · BMJ Oncology (2024) | TGRS Research Map | TGRS